Kangxinuo (688185.SH): Inhaled tuberculosis vaccine approved for clinical trials in Indonesia.

Chinatong Finance APP news, Kangxinuo (688185.SH) announced that the inhaled lung tuberculosis vaccine (Type 5 adenovirus vector) developed by the company recently obtained clinical trial approval from the Indonesia Food and Drug Administration ("BPOM"). The Phase I clinical trial aims to explore the safety and immunogenicity of a single dose of inhaled lung tuberculosis vaccine (Type 5 adenovirus vector) in adults aged 18-49.